Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

SRSF2 Mutation Cooperates with ASXL1 Mutation to Promote the Development of Myeloproliferative Variant of Chronic Myelomonocytic Leukemia

Jiaojiao Bai, Chen Qiu, Ming Yao, Chengxin Deng, Minming Li, Suxia Geng, Junfei Huang, Yangpeng Chen, Yuan Zhou, Xin Du

Blood (2024) 144 (Supplement 1): 6690.

https://doi.org/10.1182/blood-2024-205576

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen

Xin Huang, Minming Li, Ping Wu, Chengxin Deng, Zesheng Lu, Yulian Wang, Suxia Geng, Chengwei Luo Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2024) 144 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2024-204516

Published: 2024

Journal Articles

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Blood (2024) 144 (Supplement 1): 6014.

https://doi.org/10.1182/blood-2024-210211

Published: 2024

Journal Articles

ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China

Blood (2023) 142 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2023-188196

Published: 2023

Journal Articles

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Lisi Huang, Suxia Geng, Yulian Wang, Zesheng Lu, Chengxin Deng, Xin Huang, Minming Li, Lingji Zeng, Qiong Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2023-185222

Published: 2023

Journal Articles

Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML

Xin Huang, Chengxin Deng, Minming Li, Zesheng Lu, Ping Wu, Qiong Luo, Suxia Geng, Lingji Zeng, Yulian Wang, Hui Zhou, Jianyu Weng, Xin Du

Blood (2023) 142 (Supplement 1): 5941.

https://doi.org/10.1182/blood-2023-186010

Published: 2023

Journal Articles

Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia

Ruohao Xu, Suxia Geng, Lingji Zeng, Chengxin Deng, Xin Huang, Minming Li, Ping Wu, Peilong Lai, Jianyu Weng, Xin Du

Blood (2023) 142 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2023-189197

Published: 2023

Journal Articles

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Peilong Lai, Mingyan Wu, Minming Li, Chengxin Deng, Zesheng Lu, Chenwei Luo, Xin Huang, Pengjun Liao, Lisi Huang, Ping Wu, Wang Yulian, Changchun Wan, Wei Ling, Liye Zhong, Suijing Wu, Xin Du, MD PhD, Jianyu Weng, MD

Blood (2018) 132 (Supplement 1): 5229.

https://doi.org/10.1182/blood-2018-99-116234

Published: 2018

Journal Articles

Predictive Factors of Treatment Response to Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Ping Wu, Xin Du, Jianyu Weng, Chengxin Deng, Suxia Geng, Zesheng Lu, Peilong Lai, Xin Huang, Chengwei Luo

Blood (2015) 126 (23): 5199.

https://doi.org/10.1182/blood.V126.23.5199.5199

Published: 2015

Journal Articles

Analysis of the Expression of PHTF1 and Related Genes in Acute Lymphoblastic Leukemia

Xin Huang, Suxia Geng, Jianyu Weng, Zesheng Lu, Linji Zeng, Minming Li, Chengxin Deng, Xiuli Wu, Yangqiu Li, Xin Du

Blood (2015) 126 (23): 4988.

https://doi.org/10.1182/blood.V126.23.4988.4988

Published: 2015

Journal Articles

The Expression of the Co-Inhibitory Molecule PD-1 and Its Ligand PD-L1 in Patients with MDS

Suxia Geng, Jianyu Weng, Xin Huang, Ping Wu, Chengxin Deng, Peilong Lai, Xin Du

Blood (2015) 126 (23): 5212.

https://doi.org/10.1182/blood.V126.23.5212.5212

Published: 2015

Journal Articles

Effects of Decitabine and Homoharringtonine in Combination in Leukemia Cell Lines

Suxia Geng, Han Yao, Jianyu Weng, Xin Huang, Ping Wu, Chengxin Deng, Zesheng Lu, Xin Du

Blood (2015) 126 (23): 5229.

https://doi.org/10.1182/blood.V126.23.5229.5229

Published: 2015

Journal Articles

Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia

Xiaomei Chen, Jianyu Weng, Yulian Wang, Chengxin Deng, Chengwei Luo, Pengjun Liao, Minming Li, Xin Huang, Peilong Lai, Lisi Huang, Zhi Cao, Changchun Wan, Liye Zhong, Suijing Wu, Zesheng Lu, Xiaoli Zou, Xin Du

Blood (2015) 126 (23): 4897.

https://doi.org/10.1182/blood.V126.23.4897.4897

Published: 2015

Journal Articles

A Clinical Study of Bone Marrow Stromal Cell Therapy in Patients with Refractory Cgvhd by Down-Regulating the Jagged2 Gene

Jianyu Weng, MD, Xin Huang, Suxia Geng, Chengwei Luo, Suijing Wu, Wei Ling, Rong Guo, Zesheng Lu, Chengxin Deng, Pengxiang Andy, Xin Du

Blood (2012) 120 (21): 4673.

https://doi.org/10.1182/blood.V120.21.4673.4673

Published: 2012

Journal Articles

Fludarabine, Cytarabine, Busulphan, and Cyclophosphamide (FABC) as Conditioning Regimen in Hematopoietic Stem Cell Transplantation for Treatment of 92 Patients with Hematologic Malignancies.

Jianyu Weng, MD, Xin Du, PhD, Suijin Wu, MD, Zesheng Lu, MD, Chengwei Luo, MD, Rong Guo, PhD, Liye Zhong, MD, Miaorong She, PhD, Chengxin Deng, Wei Ling, PhD, Xiaoli Zou, Qunhua Li, Wei Lin, Zhixin Huang

Blood (2009) 114 (22): 1147.

https://doi.org/10.1182/blood.V114.22.1147.1147

Published: 2009

Journal Articles

Mesenchymal Stem Cells Relieve Chronic GVHD Via Modulation the Ratio of CD8+CD28-/CD8+CD28+T Cells.

Jianyu Weng, MD, Xin Du, PhD, Suxia Geng, MD, Maohua Zhou, MD, Yanwen Peng, Zhen Wang, Zesheng Lu, Suijing Wu, MD, Chenwei Luo, MD, Rong Guo, PhD, Wei Ling, PhD, Chengxin Deng, Pengjun Liao, Andy Peng Xiang, Ph.D

Blood (2009) 114 (22): 4501.

https://doi.org/10.1182/blood.V114.22.4501.4501

Published: 2009

Journal Articles

Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-Versus-Host Disease.

Weng Jianyu, MD, Xin Du, MD, PhD, Xiang Peng, MD, Zhang Xiumin, MD, Suijin Wu, MD, Zesheng Lu, MD, Chengwei Luo, MD, Rong Guo, MD, Chengxin Deng, MD, Wei Ling, MD, Wei Lin, MD, Zilun Huang, MD

Blood (2007) 110 (11): 4968.

https://doi.org/10.1182/blood.V110.11.4968.4968

Published: 2007

NARROW

SRSF2 Mutation Cooperates with ASXL1 Mutation to Promote the Development of Myeloproliferative Variant of Chronic Myelomonocytic Leukemia

Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML

Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Predictive Factors of Treatment Response to Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Analysis of the Expression of PHTF1 and Related Genes in Acute Lymphoblastic Leukemia

The Expression of the Co-Inhibitory Molecule PD-1 and Its Ligand PD-L1 in Patients with MDS

Effects of Decitabine and Homoharringtonine in Combination in Leukemia Cell Lines

Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia

A Clinical Study of Bone Marrow Stromal Cell Therapy in Patients with Refractory Cgvhd by Down-Regulating the Jagged2 Gene

Fludarabine, Cytarabine, Busulphan, and Cyclophosphamide (FABC) as Conditioning Regimen in Hematopoietic Stem Cell Transplantation for Treatment of 92 Patients with Hematologic Malignancies.

Mesenchymal Stem Cells Relieve Chronic GVHD Via Modulation the Ratio of CD8+CD28-/CD8+CD28+T Cells.

Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-Versus-Host Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only